Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass

Journal of Cardiothoracic Surgery

Gábor Szabó¹  Matthias Karck¹  Béla Merkely²  Tamás Radovits²  Gábor Veres² 

[1]Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

[2]Heart and Vascular Center, Semmelweis University, Budapest, Hungary

关键词: Ischemia-reperfusion injury;    Custodiol;    Cardioplegic solution;    HTK;    Myocardial protection;    Cardiopulmonary bypass;   

Others  :  1135868
DOI  :  10.1186/s13019-015-0226-9

 received in 2014-11-03, accepted in 2015-02-10,  发布年份 2015

【 摘 要 】

Backgrounds

On the basis of Custodiol preservation and cardioplegic solution a novel cardioplegic solution was developed to improve the postischemic cardiac and endothelial function. In this study, we investigated whether its reduced cytotoxicity and its ability to reduce reactive oxygen species generation during hypoxic condition have beneficial effects in a clinically relevant canine model of CPB.

Methods

12 dogs underwent cardiopulmonary bypass with 60 minutes of hypothermic cardiac arrest. Dogs were divided into 2 groups: Custodiol (n = 6) and Custodiol-N (n = 6) (addition of L-arginin, N-α-acetyl-L-histidine and iron-chelators: deferoxamine and LK-614). Left ventricular hemodynamic variables were measured by a combined pressure-volume conductance catheter at baseline and after 60 minutes of reperfusion. Coronary blood flow, myocardial ATP content, plasma nitrate/nitrite and plasma myeloperoxidase levels were also determined.

Results

The use of Custodiol-N cardioplegic solution improved coronary blood flow (58 ± 7 ml/min vs. 26 ± 3 ml/min) and effectively prevented cardiac dysfunction after cardiac arrest. In addition, the myocardial ATP content (12,8 ± 1,0 μmol/g dry weight vs. 9,5 ± 1,5 μmol/g dry weight) and plasma nitrite (1,1 ± 0,3 ng/ml vs. 0,5 ± 0,2 ng/ml) were significantly higher after application of the new cardioplegic solution. Furthermore, plasma myeloperoxidase level (3,4 ± 0,4 ng/ml vs. 4,3 ± 2,2 ng/ml) significantly decreased in Custodiol-N group.

Conclusions

The new HTK cardioplegic solution (Custodiol-N) improved myocardial and endothelial function after cardiopulmonary bypass with hypothermic cardiac arrest. The observed protective effects imply that the Custodiol-N could be the next generation cardioplegic solution in the protection against ischemia-reperfusion injury in cardiac surgery.

【 授权许可】

   
2015 Veres et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Yang Q, He GW: Effect of cardioplegic and organ preservation solutions and their components on coronary endothelium-derived relaxing factor. Ann Thorac Surg 2005, 80:757-67. Review
• [2]Careaga G, Salazar D, Tellez S, Sanchez O, Borrayo G, Argulero R: Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cadioplegic solution on the perioperative period in open heart surgery subjects. Arch Med Red 2001, 32:296-9.
• [3]Robinson LA, Schwarz GD, Goddard DB, Fleming WH, Galbraith TA: Myocardial protection for acquired heart disease surgery: results of a national survey. Ann Thorac Surg 1995, 59:361-72.
• [4]Guru V, Omura J, Alghamdi AA, Weisel R, Fremes SE: Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trials. Circulation 2006, 114:I331-8.
• [5]Braathen B, Jeppsson A, Scherstén H, Hagen OM, Vengen Ø, Rexius H, et al.: One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study. J Thorac Cardiovasc Surg 2011, 141:995-1001.
• [6]Scrascia G, Guida P, Rotunno C, De Palo M, Mastro F, Pignatelli A, et al.: Myocardial protection during aortic surgery: comparison between Bretschneider-HTK and cold blood cardioplegia. Perfusion 2011, 26:427-33.
• [7]Rauen U, Kerkweg U, DeGroot H: Iron-dependent vs. iron-independent cold-induced injury to cultured rat hepatocytes: a comparative study in physiological media and organ preservation solutions. Cryobiology 2007, 54:77-86.
• [8]Rauen U, Klempt S, de Groot H: Histidine-induced injury to cultured liver cells, effects of histidine derivatives and of iron chelators. Cell Mol Life Sci 2007, 64:192-205.
• [9]Pizanis N, Gillner S, Kamler M, de Groot H, Jakob H, Rauen U: Cold-induced injury to lung epithelial cells can be inhibited by iron chelators - implications for lung preservation. Eur J Cardiothorac Surg 2011, 40:948-55.
• [10]Wu K, Türk TR, Rauen U, Su S, Feldkamp T, de Groot H, et al.: Prolonged cold storage using a new histidine-tryptophan-ketoglutarate-based preservation solution in isogeneic cardiac mouse grafts. Eur Heart J 2011, 32:509-16.
• [11]Pizanis N, Petrov A, Heckmann J, Wiswedel I, Wohlschläger J, de Groot H, et al.: A new preservation solution for lung transplantation: Evaluation in a porcine transplantation model. J Heart Lung Transplant 2012, 31:310-7.
• [12]Bahde R, Palmes D, Gemsa O, Minin E, Stratmann U, de Groot H, et al.: Attenuated cold storage injury of rat livers using a modified HTK solution. J Surg Res 2008, 146:49-56.
• [13]Radovits T, Lin LN, Zotkina J, Koch A, Rauen U, Köhler G, et al.: Endothelial dysfunction after long-term cold storage in HTK organ preservation solutions: effects of iron chelators and N-alpha-acetyl-L-histidine. J Heart Lung Transplant 2008, 27:208-16.
• [14]Loganathan S, Radovits T, Hirschberg K, Korkmaz S, Koch A, Karck M, et al.: Effects of Custodiol-N, a novel organ preservation solution, on ischemia/reperfusion injury. J Thorac Cardiovasc Surg 2010, 139:1048-56.
• [15]Wallace A, Lam HW, Nosé PS, Bellows W, Mangano DT: Changes in systolic and diastolic ventricular function with cold cardioplegic arrest in man. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. J Card Surg 1994, 9:497-502.
• [16]Szabó G, Seres L, Soós P, Gorenflo M, Merkely B, Horkay F, et al.: Tetrahydrobiopterin improves cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg 2011, 40:695-700.
• [17]Rauen U, de Groot U: New insights into the cellular and molecular mechanisms of cold storage injury. J Investig Med 2004, 52:299-309.
• [18]Petrat F, de Groot H, Sustmann R, Rauen U: The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem 2002, 383:489-502.
• [19]Rauen U, Petrat F, Li T, De Groot H: Hypothermia injury/cold-induced apoptosis–evidence of an increase in chelatable iron causing oxidative injury in spite of low O2-/H2O2 formation. FASEB J 2000, 14:1953-64.
• [20]Soos P, Andrasi T, Buhmann V, Kohl B, Vahl C, Hagl S, et al.: Myocardial protection after systemic application of L-arginine during reperfusion. J Cardiovasc Pharmacol 2004, 43:782-8.
• [21]Andrews DT, Sutherland J, Dawson P, Royse AG, Royse C: L-arginine cardioplegia reduces oxidative stress and preserves diastolic function in patients with low ejection fraction undergoing coronary artery surgery. Anaesth Intensive Care 2012, 40:99-106.
• [22]Schröder C, Heintz A, Pexa A, Rauen U, Deussen A: Preclinical evaluation of coronary vascular function after cardioplegia with HTK and different antioxidant additives. Eur J Cardiothorac Surg 2007, 31:821-6.
• [23]Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, et al.: Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003, 35:790-6.
• [24]Loria V, Dato I, Graziani F, Biasucci LM: Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008, 2008:135625.
• [25]Rauen U, Polzar B, Stephan H, Mannherz HG, de Groot H: Cold-induced apoptosis in cultured hepatocytes and liver endothelial cells: mediation by reactive oxygen species. FASEB J 1999, 13:155-68.